Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure
Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure: a Multicenter Prospective Observational Registry
Careggi Hospital
1,000 participants
Jul 16, 2019
OBSERVATIONAL
Conditions
Summary
The use of extracorporeal blood purification therapies (EBPT) is becoming increasingly widespread worldwide in everyday clinical practice, particularly in the critical care setting. Nonetheless, most of the clinical trials aimed at exploring the effect of EBPT on patients' long-term outcomes have failed to demonstrate consistent results regarding 28 day- or hospital- mortality rates. The aim of this observational prospective registry is to evaluate if there is a cluster of critically ill patients that mostly benefits from extracorporeal blood purification therapies with different EBPTs.
Eligibility
Inclusion Criteria4
- critically ill patients in the ICU
- one of this EPB therapy:
- CRRT/IHD/Hybrid therapies for support//replacement renal function
- immunomodulation achieved by "high cut-off membranes", "endotoxins and/or cytokines adsorbent membranes" or by high-volume hemofiltration
Exclusion Criteria1
- patients treated only by Cytosorb® and/or Toraymyxin® therapies
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Every center will prescribe EBPT with commercial membranes in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
Locations(15)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04033224